Physician profile
Alison Bailey
NPI 1376002238
$1,839.84
in general payments reported to CMS, 2019-2025
15 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $535 · 2023: $735 · 2024: $49.38 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,058.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $710.46 | 2021-2023 | |
| Galderma Laboratories, L.P. | $258.08 | 2023 | Epsolay, Oracea |
| Ucb, INC. | $242.24 | 2022-2025 | Cimzia, Bimzelx |
| Sun Pharmaceutical Industries INC. | $135.61 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.54 | 2023 | Spevigo |
| Revance Therapeutics, INC. | $94.37 | 2025 | Daxi |
| Incyte Corporation | $89.71 | 2022 | |
| Lilly USA, LLC | $41.18 | 2025 | Taltz, Ebglyss |
| Abbvie INC. | $39.67 | 2024-2025 | |
| Cvrx, INC. | $26.01 | 2024 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $21.74 | 2025 | |
| Almirall LLC | $18.63 | 2025 | Klisyri |
| Mimedx Group, INC. | $14.34 | 2025 | |
| Stemline Therapeutics INC. | $12.72 | 2021 | |
| Organon LLC | $12.54 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.